Corporate Management Information Main Article

U.S.-based Daiichi Sankyo Leaders

Our leadership team inspires and challenges every aspect of the organization to develop life-changing solutions for the patients of today and tomorrow. Along with their peers who sit overseas, this dynamic and experienced group of U.S.-based leaders enable us to create innovative medicines that can change the standard of care.

Corporate Management Bio

Corporate Management

Ken Keller

Chairman of the Board, President and Chief Executive Officer of Daiichi Sankyo, Inc. and Global Head of the Daiichi Sankyo Oncology Business

Ken Takeshita, MD

Global Head, Research & Development

Daniel Switzer

Head of U.S. Oncology Business Division

Ken Keller

Chairman of the Board, President and Chief Executive Officer of Daiichi Sankyo, Inc. and Global Head of the Daiichi Sankyo Oncology Business

Rich Jones

Vice President, Global Oncology Business Strategy & Analytics

Ken Takeshita, MD

Global Head, Research & Development

Michael Grosso, MD, FACS

Global Head of Specialty Medicine Clinical Development

Dalal Nesheiwat, PharmD

Global Head Clinical Science

Marielle Cohard Radice, MD

Global Head of Development Operations

Mark Rutstein, MD

Head of Global Oncology Clinical Development

Michele Schmidt

Head of Global Asset and Portfolio Management

Dale E. Shuster, PhD

Head of Global Precision Medicine

Daniel Switzer

Head of U.S. Oncology Business Division

Brian Hauser

Vice President, U.S. Business Operations

Kara Reheis

Vice President, U.S. Marketing

Kevin R Forrest

National Sales Director, Oncology Breast

Lerryn Trzcinski

Vice President, U.S. Market Access

Matt Siegel

National Sales Director, Hematology and Supportive Care

Fussy Tracy

National Sales Director, Oncology Lung

Stu Mackey, JD

Global Head Business Development

Matt Allegrucci

Chief Compliance Officer, Head of Global Compliance & Risk Management

James Felix

Head of Global Digital Transformation (DX), Chief Digital Transformation Officer

Amy Todd Klug, Esq.

General Counsel & Secretary

Simon King

Chief People Officer

Mila Tartakovsky

Head of US Finance and Global Oncology Finance

Last Updated: September 2024

Corporate Management Information Main Article

U.S.-based Daiichi Sankyo Leaders

Corporate Management Bio

Corporate Management

Ken Keller

Ken Takeshita, MD

Daniel Switzer

Global Oncology Business (U.S.-based leaders)

Ken Keller

Rich Jones

Research & Development (U.S.-based leaders)

Ken Takeshita, MD

Michael Grosso, MD, FACS

Dalal Nesheiwat, PharmD

Marielle Cohard Radice, MD

Mark Rutstein, MD

Michele Schmidt

Dale E. Shuster, PhD

U.S. Oncology Business

Daniel Switzer

Brian Hauser

Kara Reheis

Kevin R Forrest

Lerryn Trzcinski

Matt Siegel

Fussy Tracy

Other U.S.-based leaders

Stu Mackey, JD

Matt Allegrucci

James Felix

Amy Todd Klug, Esq.

Simon King

Mila Tartakovsky

Breadcrumb

Corporate Management Information Main Article

U.S.-based Daiichi Sankyo Leaders

Corporate Management Bio

Corporate Management

Ken Keller

Ken Takeshita, MD

Daniel Switzer

Global Oncology Business (U.S.-based leaders)

Ken Keller

Rich Jones

Research & Development (U.S.-based leaders)

Ken Takeshita, MD

Michael Grosso, MD, FACS

Dalal Nesheiwat, PharmD

Marielle Cohard Radice, MD

Mark Rutstein, MD

Michele Schmidt

Dale E. Shuster, PhD

U.S. Oncology Business

Daniel Switzer

Brian Hauser

Kara Reheis

Kevin R Forrest

Lerryn Trzcinski

Matt Siegel

Fussy Tracy

Other U.S.-based leaders

Stu Mackey, JD

Matt Allegrucci

James Felix

Amy Todd Klug, Esq.

Simon King

Mila Tartakovsky